Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Swiss Exchange  -  11:30 2022-10-07 am EDT
75.54 CHF    0.00%
07:23aNOVARTIS AG : Deutsche Bank reaffirms its Sell rating
MD
10/05NOVARTIS AG : Goldman Sachs maintains a Buy rating
MD
10/03Imugene Names Chief Medical Officer; Shares Rise 3%
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis-BeiGene Liver Cancer Drug Works As Well As Bayer's Nexavar in Phase 3 Study

08/09/2022 | 10:28am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BEIGENE, LTD. -3.90% 134.87 Delayed Quote.-48.20%
NOVARTIS AG 0.00% 75.54 Delayed Quote.-5.90%
All news about NOVARTIS AG
07:23aNOVARTIS AG : Deutsche Bank reaffirms its Sell rating
MD
10/05NOVARTIS AG : Goldman Sachs maintains a Buy rating
MD
10/03Imugene Names Chief Medical Officer; Shares Rise 3%
MT
09/29Moderna Adds New Role Ahead of Product Launches
DJ
09/28Pm(noc) Regulations : Five-year Anniversary Of Major Amendments
AQ
09/28Europe's generic drugmakers say they may cut output due to energy bills
RE
09/28Europe's generic drugmakers may cut output due to surging energy bills
RE
09/27Monsenso participates in new, large innovation project
AQ
09/27Europe's generic drugmakers may cut output due to surging energy bills
RE
09/27Sandoz Granted Leave To Add New Allegations On Condition Of Trial Adjournment And Exten..
AQ
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2022 52 222 M - -
Net income 2022 8 791 M - -
Net Debt 2022 8 452 M - -
P/E ratio 2022 18,7x
Yield 2022 4,32%
Capitalization 166 B 166 B -
EV / Sales 2022 3,35x
EV / Sales 2023 3,30x
Nbr of Employees 108 000
Free-Float 87,1%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 25
Last Close Price 76,16 $
Average target price 89,79 $
Spread / Average Target 17,9%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Non-Executive Chairman
Shreeram Aradhye Chief Medical Officer
Steffen Lang President-Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-5.90%166 889
JOHNSON & JOHNSON-5.35%425 691
ELI LILLY AND COMPANY20.11%316 361
ROCHE HOLDING AG-14.13%271 357
ABBVIE INC.3.61%248 046
PFIZER, INC.-25.28%241 836